Clinical Trial

Respiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion

Study acronym: EILO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The overall objectives of the proposed research are to: 1. Evaluate the diagnostic validity of a novel mechano-acoustic signatures of task-characteristic activity during symptomatic and asymptomatic breathing in Exercise-Induced Laryngeal Obstruction (EILO) patients with the use of a novel miniature, soft wearable skin-mounted device, 2. Identify the mechanism/s of paradoxical respiratory control in EILO by quantifying the relationship between pulmonary mechanics, partial pressure of carbon dioxide (PCO2) maintenance, and vocal fold aperture prior to and during symptomatic and asymptomatic exercise ventilation, and 3. Identify unique biophysiological factors contributing to EILO among exercisers with and without EILO. Findings will be highly novel and clinically significant for early identification and management of EILO. The main study will enroll 60 participants with EILO and 60 without EILO to complete three separate visits: 1. Exercise treadmill study 2. Free running with the device on the neck 3. Undergoing MRI (Magnetic Resonance Imaging) of the vocal tract. An additional substudy limited to the mechanoacoustic device will enroll 10 additional participants (5 healthy and 5 with EILO). These participants will complete a single study visit during which the mechano-acoustic device will be worn during four sequential conditions.
Protocol Amendment History 2 changes
critical Phase changed: Early Phase 1 -> Phase 2 2026-08-15
minor Trial arms changed: 3 -> 2 2026-08-15
Trial Details
NCT Number NCT07420530
Lead Sponsor Indiana University
Collaborators: Purdue University, National Jewish Health, National Institute on Deafness and Other Communication Disorders (NIDCD)
Conditions Exercise-Induced Vocal Cord Dysfunction, Paradoxical Vocal Fold Motion, Vocal Cord Dysfunction
Enrollment 130 participants
Start Date 2026-08-12
Primary Completion 2032-01-20 (estimated)
Study Completion 2032-01-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-14